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AbsTrACT
Objectives a better understanding of Chlamydia 
trachomatis infection (chlamydia)–related sequelae can 
provide a framework for effective chlamydia control 
strategies. the objective of this study was to estimate 
risks and risk factors of pelvic inflammatory disease (PiD), 
ectopic pregnancy and tubal factor infertility (tFi) with a 
follow-up time of up until 8 years in women previously 
tested for chlamydia in the chlamydia Screening 
implementation study (cSi) and participating in the 
netherlands chlamydia cohort Study (neccSt).
Methods Women who participated in the cSi 
2008–2011 (n=13 498) were invited in 2015–2016 for 
neccSt. chlamydia positive was defined as a positive 
cSi-Pcr test, positive chlamydia serology and/or self-
reported infection (time dependent). Data on PiD, ectopic 
pregnancy and tFi were collected by self-completed 
questionnaires. incidence rates and Hrs were compared 
between chlamydia-positive and chlamydia-negative 
women corrected for confounders.
results Of 5704 women included, 29.5% (95% ci 
28.3 to 30.7) were chlamydia positive. the incidence rate 
of PiD was 1.8 per 1000 person-years (py) (1.6 to 2.2) 
overall, 4.4 per 1000 py (3.3 to 5.7) among chlamydia 
positives compared with 1.4 per 1000 py (1.1 to 1.7) 
for chlamydia negatives. For tFi, this was 0.4 per 1000 
py (0.3 to 0.5) overall, 1.3 per 1000 py (0.8 to 2.1) and 
0.2 per 1000 py (0.1 to 0.4) among chlamydia positives 
and negatives, respectively. and for ectopic pregnancy, 
this was 0.6 per 1000 py (0.5 to 0.8) overall, 0.8 per 
1000 py (0.4 to 1.5) and 0.6 per 1000 py (0.4 to 0.8) for 
chlamydia negatives. among chlamydia-positive women, 
the strongest risk factor for PiD was symptomatic versus 
asymptomatic infection (adjusted Hr 2.88, 1.4 to 4.5) 
and for tFi age <20 versus >24 years at first infection 
(Hr 4.35, 1.1 to 16.8).
Conclusion We found a considerably higher risk for PiD 
and tFi in chlamydia-positive women, but the incidence 
for ectopic pregnancy was comparable between 
chlamydia-positive and chlamydia-negative women. 
Overall, the incidence rates of sequelae remained low.
Trial registration ntr-5597.
bACkgrOund
Chlamydia trachomatis infection (chlamydia) prev-
alence has remained high with an estimated annual 
number of infections of 130 million worldwide 
in 2012.1 Chlamydia disproportionately affects 
women of reproductive age with a prevalence of 
4.0% compared with 2.8% among men.1 Studies 
indicate that 10%–30% of women experience one 
or more chlamydia episodes.2 3 With up to 70% of 
infections being asymptomatic, many women are 
left untreated and are prone to chlamydia-related 
sequelae4 such as pelvic inflammatory disease (PID), 
ectopic pregnancy and tubal factor infertility (TFI).5
Proportions of PID following chlamydia were 
found between 3.0% and 30.0%,6–10 for ectopic 
pregnancy between 0.2% and 2.7%,7 9–11 and for 
TFI between 0.1% and 6.0%.6 7 12 Questions remain 
concerning true risks of sequelae due to study 
limitations, such as small sample size or limited 
follow-up time,13 unavoidable misclassification of 
chlamydia status as it is primarily based on incident 
(nucleic acid amplification test (NAAT)) tests,9 or 
lack of information on potential confounders such 
as sexual risk behaviour, demographic data and 
lifestyle factors in cohort studies based on large 
medical databases.10 These limitations need to be 
addressed to determine true risks of chlamydia-re-
lated sequelae.
The only way to interrupt the course of a chla-
mydia infection is to test and treat women at risk 
for chlamydia. However, there is no scientific 
evidence that screening decreases prevalence.2 14 15 
It might be more effective to move towards targeted 
screening of women at highest risk for developing 
sequelae since the clinical course of chlamydia 
differs greatly between individuals and depends on 
pathogen factors, environmental factors and host 
factors.9 16–19 To study chlamydia-related sequelae 
and risk factors, the Netherlands Chlamydia Cohort 
Study (NECCST) was initiated in 2015. NECCST 
is an ongoing cohort study among Dutch women 
of reproductive age and a follow-up study of the 
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2008–2011 Chlamydia Screening Implementation programme 
(CSI) in which all women were tested for chlamydia.20 We esti-
mated risks of PID, ectopic pregnancy and TFI up to 8 years 
after chlamydia infection in women taking into account sexual 
risk behaviour, demographics and lifestyle factors. To identify 
women with high risk for sequelae, potential risk factors were 
evaluated.
METhOds
study design and participants
NECCST is a cohort of women of reproductive age to be 
followed until 2022. The design has been described previously.20 
Briefly, women between 16 and 29 years participated in 2008–
2011 in the CSI.14 CSI participants were tested for chlamydia via 
PCR test ≥1 with a maximum of four times in a 4-year period. 
In case of chlamydia-positive PCR outcomes, participants were 
referred to the general practitioner or STI clinic for treatment. 
CSI women were traced in municipal registers and invited for 
participation in NECCST (online supplementary figure S1).
Procedures
In 2015–2016, women were invited and informed by regular 
mail and email. The first NECCST data collection moment 
included an electronic questionnaire followed by a test kit for 
self-collection of blood via a finger-prick for chlamydia IgG 
analyses as a marker for previous infection. The initial NECCST 
questionnaire retrospectively inquired about previous chlamydia 
infections, PID, ectopic pregnancy and TFI. Additionally, the 
NECCST questionnaire addressed demographic factors, sexual 
behaviour, other STIs, contraceptive use and health characteris-
tics. For all events, timing in calendar year was asked. This was 
done to reconstruct a timeline for time-to-event analysis. Subse-
quently, CSI data about chlamydia PCR results, self-reported 
chlamydia infections and age of sexual debut acquired via the 
CSI-questionnaires were merged with NECCST data.
Chlamydia IgG antibodies were determined in self-collected 
capillary blood samples, collected in tubes (BD Microtainer SST, 
USA) and returned to the laboratory via mail. Serum samples 
were stored at −20˚C until thawed for ELISA with a sensitivity 
of 71% and specificity of 97% (Medac CT IgG ELISA plus, 
Wedel, Germany).21 22
definitions and outcomes
Chlamydia positivity was defined as a positive PCR test outcome 
in the CSI study (CSI-PCR+), and/or the presence of chlamydia 
IgG in serum and/or a self-reported chlamydia infection. From 
the year of first chlamydia infection onwards, a woman was 
classified as chlamydia positive and remained positive. If year 
of first infection was unknown, that is, in women with a posi-
tive chlamydia IgG result only, multiple imputations were done 
for the Cox model analyses using truncated regression with 15 
simulation datasets23 to estimate time of first chlamydia infec-
tion following sexual debut based on available data from women 
with a known year of first infection. Women were classified as 
chlamydia negative when they were CSI-PCR negative, had no 
chlamydia antibodies and did not report a previous infection.
The primary outcomes were PID, ectopic pregnancy and TFI:
1. PID was defined as a self-reported episode of inflammation 
of the ovaries, uterus and/or fallopian tubes, diagnosed by 
a medical professional. To obtain more information, wom-
en were asked whether the diagnosis was based on reported 
symptoms, physical examination, laboratory testing (either 
blood or vaginal swab examination), laparoscopy or whether 
this was unknown to them. Furthermore, we asked if women 
had been admitted to the hospital for the PID episode.
2. Ectopic pregnancy was defined as a self-reported extrauter-
ine pregnancy. Women who were/had been pregnant were 
asked if they had experienced an ectopic pregnancy, and if 
so, the number and year of ectopic pregnancies.
3. TFI was defined as self-reported infertility caused by abnor-
malities of the tubes (possibly combined with other causes of 
infertility), diagnosed by a medical professional. All women 
who reported infertility were asked which fertility exam-
inations had been conducted, that is, chlamydia antibody 
testing, hysterosalpingography, contrast ultrasonography, 
laparoscopy or ‘none of the above’. Although self-reported 
TFI was found a reliable measure of TFI in the Netherlands,24 
we validated a subset of self-reported TFI cases. Substantial 
agreement (Kappa value 0.73) between self-reported TFI and 
medical registers was found in the first NECCST round.
Exposure time in time-to-event analyses was defined as the 
total number of person-years, starting from when a woman 
became sexually active (or minimum age defined at 12 years 
for earlier reports). Exposure time ended at last data collection 
point or when a specific outcome event occurred.
statistical analyses
Incidence rates (calculated as the number of new outcomes 
divided by total person-years at risk) of primary study endpoints 
PID, ectopic pregnancy and TFI were described.
The association between chlamydia status and each of the 
primary study endpoints was retrospectively assessed through 
Kaplan-Meier curves and univariable and multivariable Cox 
proportional-hazards regression models. Risks were expressed 
in HRs. Chlamydia status was included as a time-dependent 
variable. The following variables were considered potential 
confounders and included in the model if there was a ≥10% 
change in the regression coefficient: age (time-varying), gonor-
rhoea infection, migration background (Western vs non-Western, 
based on parental country of birth), educational level low/middle 
versus high (ie, low/medium: no education, primary education 
only, lower general secondary education, and vocational educa-
tion; high level: all other education levels), lifetime sex partners, 
age of sexual debut, condom use with casual partner, smoking 
behaviour and intrauterine device (IUD) insertion. The propor-
tional-hazard assumption was checked using log–log plots and 
testing Schoenfeld residuals.
To be able to identify chlamydia-positive women with a high 
risk for sequelae, risk factors for PID and TFI were determined 
by Cox regression models. Included risk factors were demo-
graphics, sexual risk behaviour, contraceptive use, chlamydia 
infection variables and serology (positive/negative outcome). All 
variables were assessed via univariable analysis and those asso-
ciated (p<0.10) with the outcome were entered via backward 
stepwise selection into the multivariable model.
To establish how closely risk factors were associated with the 
outcomes regardless of chlamydia status, factors were univari-
ably tested with each outcome.
Multiple imputations and analyses were performed in STATA 
(V.14; StataCorp, College Station, Texas, USA).
sensitivity analyses
First, we repeated analyses without multiple imputations for 
women with an unknown year of chlamydia infection. Second, 
analyses were repeated including only women with CSI-PCR-pos-
itive test results because CSI-PCR results have high sensitivity 
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Table 1 Characteristics of the study population by chlamydia status 








n (%) P value
5704 (100%) 4022 (70.5%) 1682 (29.5%)
Age (years) mean (SD) 31.1 (3.8) 31.2 (3.8) 30.9 (3.8) 0.003*
Chlamydia positivity in CSI-
PCR n (%)
908 (15.9) 908 (54.0)
Gonorrhoea positivity n (%) 112 (2.0) 32 (0.8) 80 (4.8) <0.001*
Migration background <0.001*
  Western 4565 (80.0) 3382 (84.1) 1183 (70.3)
  Non-Western 869 (15.2) 464 (11.5) 405 (24.1)
  Unknown 270 (4.7) 176 (4.4) 94 (5.6)
Educational level†‡ <0.001*
  Low/middle 1170 (20.5) 661 (16.5) 509 (30.3)
  High 4529 (79.5) 3358 (83.6) 1171 (69.7)
Age at sexual debut mean 
(SD)
16.9 (2.4) 17.2 (2.4) 16.4 (2.1) <0.001*
Lifetime sex partners <0.001*
 <6 1797 (31.5) 1.499 (37.3) 298 (17.7)
  6–12 2033 (35.6) 1424 (35.4) 609 (36.2)
 >12 1874 (32.9) 1099 (27.3) 775 (46.1)
Condom use with casual 
partners§
<0.001*
  Never/not often 340 (6.0) 243 (6.1) 97 (5.8)
  Sometimes 1807 (31.7) 1100 (27.4) 707 (42.1)
  Always/mostly 2579 (45.9) 1890 (47.1) 720 (42.9)
  No casual partners 936 (16.4) 780 (19.4) 156 (9.3)
Use of IUD 0.230
  Never 3672 (64.4) 2609 (64.9) 1063 (63.2)
  At least once 2032 (35.6) 1413 (35.1) 619 (36.8)
Smoking <0.001*
  Never 2264 (39.7) 1724 (42.9) 540 (32.1)
  Sometimes/in the past 2843 (49.8) 1960 (48.7) 883 (52.5)
  Daily 597 (10.5) 338 (8.4) 259 (15.4)
No of chlamydia tests <0.001*
  1 1042 (18.3) 931 (23.2) 111 (6.6)
  2 1539 (27.0) 1222 (30.4) 317 (18.9)
  3 1485 (26.0) 1032 (25.7) 453 (26.9)
 >3 1638 (28.7) 837 (20.8) 801 (47.6)
Chlamydia symptoms¶ 
  No – 952 (56.6)
  Yes – 730 (43.4)
No of chlamydia infections** 
  1 – 1325 (78.8)
  2 – 291 (17.3)
  3 or more – 66 (3.9)
Age at first chlamydia infection 
 <20 – 305 (20.8)
  20–24 – 640 (43.7)
 >24 – 519 (35.5)
Chlamydia IgG antibodies (serology) 
  No 3101 (54.4) 2572 (64.0) 529 (31.5)
  Yes 569 (10.0) – 569 (33.8)
  Unknown 2034 (35.7) 1450 (36.0) 584 (34.7)
Chlamydia positive was defined as a positive PCR-test outcome in the CSI study (CSI-PCR), and/or the presence of 
chlamydia IgG and/or a self-reported chlamydia infection.
*Statistically significant, p<0.05.
†Educational level: low/medium level of education: no education, primary education only, lower general secondary 
education and vocational education; high level of education: all other education levels. Chlamydia symptoms were 
vaginal discharge, abdominal pain or pain during intercourse and/or intermittent vaginal bleeding.
‡At start of NECCST and based on 5699 observations, 5 missing.
§Based on 5693 observations, 11 missing.
¶based on 1665 observations, 15 missing values.
**Based on 1639 observations, 43 missing.
CSI, Chlamydia Screening Implementation; IUD, intrauterine device; NECCST, Netherlands Chlamydia Cohort Study.
and specificity and no recall bias. Third, repeated analyses for 
ectopic pregnancy and TFI were restricted to women who had 
been pregnant at least once or who had ever tried to become 
pregnant. Fourth, due to residual uncertainties in PID diagnosis, 
we repeated analyses for PID including only hospitalised cases 
and for PID cases that occurred later than year of first chlamydia 
infection. This was not indicated for ectopic pregnancy and TFI 
since for both only one case occurred in the same year as the first 
chlamydia infection.
rEsulTs
Between November 2015 and August 2016, 13 498/14 865 
(91.9%) of eligible CSI women were able to be retraced and 
invited for NECCST. Moreover, 5704 (42.3%) women were 
enrolled and completed the initial questionnaire (online 
supplementary figure S1). In total, 1682 (29.5%, 95% CI 
28.3 to 30.7) women were ever chlamydia positive and 4022 
(70.5%, 95% CI 0.69 to 0.72) had remained chlamydia nega-
tive. Chlamydia positivity was based on 1469 (87.3%) self-re-
ported infections, of which 341 (23.2%) also tested PCR 
positive during CSI, and 360 (24.5%) also tested positive for 
chlamydia IgG. Chlamydia antibody testing was done in 3670 
(65%) women of whom 15.5% (95% CI 14.3 to 16.7) was 
positive. The remaining chlamydia positives (n=213) only 
had a positive chlamydia IgG test (n=208), were only PCR 
positive in CSI (n=4) or were both chlamydia IgG and PCR 
positive (n=1) but did not report this (online supplementary 
figure S2). Multiple imputations to impute time for first chla-
mydia were used for 226/1682 (13.4%) chlamydia-positive 
women. These women were slightly older (31.6 vs 30.8 years) 
and had less lifetime partners and more condom use compared 
with chlamydia positives with known date of infection. Mean 
age at start of exposure time (sexual debut) was 16.9 (SD 2.4) 
years and mean exposure time was 14.2 (SD 3.9) years. Total 
exposure time was 86 610 person-years (py). Characteristics 
of study participants are presented in table 1.
Pelvic inflammatory disease
Women with an episode of PID before exposure time were 
excluded (n=6). In total, 159 (2.8%, 95% CI 2.4 to 3.2) 
women reported at least one episode of PID, of which 57 
(35.9%) were admitted to hospital. Of 33 (20.8%) women 
with >1 reported PID episode, 45.5% were admitted to 
hospital at least once. The incidence rate of PID was 1.8 per 
1000 py (95% CI 1.6 to 2.2). Chlamydia positives had a higher 
incidence rate of 4.4 episodes of PID per 1000 py (95% CI 3.3 
to 5.7) compared with 1.4 per 1000 py (95% CI 1.1 to 1.7) 
for chlamydia negatives. Incidence rates among the different 
chlamydia parameters, CSI-PCR+, chlamydia antibody pres-
ence or self-reported infections, were 4.5 (95% CI 2.6 to 7.9), 
5.2 (95% CI 2.9 to 9.1) and 4.1 (95% CI 2.8 to 5.8) per 1000 
py, respectively. In multivariable analysis, adjusted for age and 
educational level, chlamydia positivity remained strongly asso-
ciated with PID (adjusted HR (aHR) 2.22, 95% CI 1.57 to 
3.13) (table 2 and figure 1).
Ectopic pregnancy
In total, 2633 (46.2%) women were pregnant at least once or 
tried to become pregnant. Fifty-two (0.9%, 95% CI 0.7 to 1.2) 
women reported one or more ectopic pregnancies. The inci-
dence rate of ectopic pregnancy was 0.6 per 1000 py (95% CI 
0.5 to 0.8). Ectopic pregnancy rates were not different between 
chlamydia positives (0.8 per 1000 py, 95% CI 0.4 to 1.5) and 
chlamydia negatives (0.6 per 1000 py, 95% CI 0.4 to 0.8), nor 
in multivariable analysis after adjustment for age, educational 
level, number of lifetime partners and migration background 
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Table 2 Association between chlamydia positivity and pelvic inflammatory disease, ectopic pregnancy and tubal factor infertility in women 
participating in NECCST
Cases Time Crude hr Adjusted hr*†‡
n§ Person-years¶ hr 95% CI P value ahr 95% CI P value
Pelvic inflammatory disease
  Chlamydia negative 100 71 029 1 1
  Chlamydia positive 59 14 320 2.60 1.85 to 3.66 <0.0001 2.22 1.57 to 3.13 <0.0001
Ectopic pregnancy
  Chlamydia negative 41 71 412 1 1
  Chlamydia positive 11 14 684 0.99 0.49 to 1.97 0.80 0.39 to 1.63 0.5335
Tubal factor infertility
  Chlamydia negative 15 71 523 1 1
  Chlamydia positive 18 14 699 4.27 2.08 to 8.77 0.0001 4.22 2.05 to 8.69 0.0001
Chlamydia positive was defined as a positive PCR-test outcome in the CSI study (CSI-PCR), and/or the presence of chlamydia IgG and/or a self-reported chlamydia infection. For 
these analyses, multiple imputations were used to estimate time of first chlamydia infection in women without a known first year of chlamydia infection.
*PID model adjusted for age (time-varying) and educational level.
†Ectopic pregnancy model adjusted for age (time-varying), educational level, number of lifetime partners and migration background.
‡Tubal factor infertility model adjusted for age (time-varying).
§Median cases of 15 multiple imputation datasets.
¶Estimated from 15 multiple imputation datasets.
aHR, adjusted HR; CSI, Chlamydia Screening Implementation; NECCST, Netherlands Chlamydia Cohort Study.
(aHR 0.80, 95% CI 0.39 to 1.63) (table 2, figure 1). Incidence 
rates among the different chlamydia parameters, CSI-PCR+, 
chlamydia antibody presence or self-reported infections, were 
0.4 (95% CI 0.1 to 2.6), 0.4 (95% CI 0.1 to 3.0) and 1.1 (95% 
CI 0.5 to 2.1) per 1000 py, respectively.
Tubal factor infertility
In total, 33 (0.6%, 95% CI 0.4 to 0.8) women reported to 
be diagnosed with TFI. The incidence rate was 0.4 per 1000 
person-years (95% CI 0.3 to 0.5). Among chlamydia positives, 
the incidence rate of TFI was considerably higher compared 
with chlamydia negatives: 1.3 per 1000 py (95% CI 0.8 to 
2.1) and 0.2 per 1000 py (95% CI 0.1 to 0.4), respectively. 
Incidence rates among the different chlamydia parameters, 
CSI-PCR+, chlamydia antibody presence or self-reported 
infections, were 1.1 (95% CI 0.4 to 3.4), 0.8 (95% CI 0.2 to 
3.4) and 1.4 (95% CI 0.8 to 2.6) per 1000 py, respectively. 
Chlamydia positivity was highly associated with TFI: aHR 
4.22 (95% CI 2.05 to 8.69) (table 2 and figure 1). The model 
was adjusted for age.
Sensitivity analyses on all three outcomes (PID, ectopic 
pregnancy, TFI) using data restrictions as indicated in method-
ology section yielded mostly similar results (figure 2).
risk factors for long-term sequelae among chlamydia-
positive women
In multivariable analyses, having had chlamydia symptoms and 
IUD insertion were associated with PID (online supplementary 
table 1). For TFI, a younger age at first chlamydia infection 
(<20 years) was the only risk factor in univariable analyses. For 
both PID and TFI, we were unable to determine an increased 
risk for women with an unnoticed chlamydia infection (chla-
mydia IgG-positive only) compared with women with a known 
and presumably treated infection.
Associations between risk factors and outcomes regardless 
of chlamydia status can be found in online supplementary 
table S2.
dIsCussIOn
We estimated risks of PID, ectopic pregnancy and TFI in a 
unique cohort of over 5500 women with up to 8 years of 
follow-up. Chlamydia positivity was strongly associated with 
PID, as shown by a twofold higher risk, and with TFI, by a 
fourfold higher risk. Incidence rates and risks on sequelae 
were comparable among all chlamydia positives (either PCR 
positive, antibody positive or self-reported). Among chlamyd-
ia-positive women, PID was found to be more common in 
women who had symptoms during infection. For TFI among 
chlamydia-positive women, young age (<20) at first chlamydia 
infection was the strongest risk factor. We did not find an asso-
ciation between chlamydia positivity and ectopic pregnancy. 
Although differences in risk between chlamydia-positive and 
chlamydia-negative women were considerable and highly 
significant, the cumulative incidence for any of the sequelae 
studied was low (<5%).
This cohort study yielded an exhaustive dataset in which 
chlamydia-related sequelae were determined. First, over 5500 
women were followed since 2008 with multiple data collec-
tion points. Second, we adopted a thorough approach in deter-
mining previous chlamydia infections using three outcome 
measures: CSI-PCR, serology and self-reporting. Thereby 
increasing the true proportion of chlamydia-positive women, 
however, we cannot completely exclude infections in the nega-
tive group due to moderate sensitivity of the chlamydia IgG 
ELISA test. Third, we were able to adjust the relation between 
chlamydia and its sequelae for multiple confounders, that is, 
sexual risk behaviour, previous pregnancies and pregnancy 
wishes, demographics and lifestyle factors. Therefore, our 
results may approach true risk estimates by reducing some 
important uncertainties.5
This study had several limitations. First, we used self-re-
ported data on PID, ectopic pregnancy and TFI and in part 
on chlamydia infections, which are subject to recall bias. In 
addition, PID diagnoses are imprecise since a non-invasive 
gold standard test is not available.25 Both over-reporting and 
diagnostic bias towards chlamydia-positive women could have 
taken place,5 possibly leading to an overestimation of the risk 
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Figure 1 Kaplan-Meier plots of time (years) by chlamydia status 
since sexual debut. (A) Pelvic inflammatory disease (PID). (B) Ectopic 
pregnancy. (C) Tubal factor infertility (TFI). Chlamydia positive was 
defined as a positive PCR-test outcome in the CSI study (CSI-PCR), and/
or the presence of chlamydia IgG and/or a self-reported chlamydia 
infection. CSI, Chlamydia Screening Implementation.
among chlamydia-positive women. TFI was based on self-re-
ports, but partly validated in medical registers, showing good 
agreement. Second, because the NECCST cohort is based on a 
sample of the CSI study, we have a non-representative sample 
which decreased generalisability of the results. Third, timing 
of events was defined in years. As PID sometimes occurred 
in the same year as the first chlamydia infection, it cannot 
be ruled out that some PID cases might have occurred before 
the first chlamydia infection. Sensitivity analyses excluding 
PID cases that occurred in the same year as the chlamydia 
infection still yielded an increased risk for chlamydia-posi-
tive women, though not significant. Thus, while the largest 
risk for PID following a chlamydia infection was in the year 
of infection, the majority of PIDs occurred thereafter. Lastly, 
to draw conclusions on a possible association between chla-
mydia and ectopic pregnancy, which remains inconclusive 
also in previous studies,9 26 longer follow-up of NECCST will 
be needed.20
Incidence rates of PID and TFI among chlamydia-positive 
women found in our study (4.4/1000 and 1.1/1000 py, respec-
tively) were comparable with results from two Danish studies 
and an Australian population-based cohort study. However, 
our incidence rate for ectopic pregnancy was lower: 0.8/1000 
py. These studies found incidence rates of 4.0–8.0/1000 py 
for PID, 2.8/1000 py for ectopic pregnancy and 0.7/1000 
py for TFI and reported cumulative incidences of 2%–3%, 
2%–3% and 0.6%, respectively.9 10 27 For PID and TFI, the 
Danish and Australian studies found smaller differences in risk 
between chlamydia positives and negatives than we did: for 
PID 1.3–1.8 and for TFI 1.3 (9, 10, 27) compared with our 
HRs of 2.2 and 4.2, respectively. A different comparison was 
made in these studies because their definition of chlamydia 
negative was based on negative test (NAAT) results, excluding 
non-tested women, who were at lower risk than women who 
tested negative.
We want to be able to identify chlamydia-positive women 
with the highest risk of complications. Identified risk factors 
can help develop chlamydia-specific prevention methods. In 
chlamydia-negative women, it is more likely that the cause 
of complications is due to causes other than chlamydia. 
The strongest risk factors for PID among chlamydia-pos-
itive women were chlamydia symptoms and insertion of an 
IUD. However, women with an IUD might be more focused 
on abdominal pain and visit a doctor earlier compared with 
women without an IUD (diagnostic bias).28 Thereby, only part 
of PID, but also ectopic pregnancy and TFI, is caused by chla-
mydia; estimated population excess fractions are between 20% 
and 30% for PID, and around 5% for ectopic pregnancy and 
30% for TFI.7
This study adds to the evidence that chlamydia increases 
the risk for PID and TFI in women even if the infection was 
treated,29 but also showed that incidence rates were small. 
However, alertness for PID in years after infection remains 
warranted among healthcare providers, especially in women 
who experienced chlamydia-related symptoms during infec-
tion. Though chlamydia is an important causative agent for 
TFI (ie, fourfold increased risk) during the 8-year follow-up 
time of our cohort, TFI was only found in 1% of women 
following chlamydia infection, in accordance with modelling 
studies.12 It is important to identify that 1% of women had 
high risk. The following step in NECCST is to assess single-nu-
cleotide polymorphisms (SNPs) associations.
The present results underscore the need for effective preven-
tion of reproductive tract complications following chlamydia 
infection. Given the small cumulative risks and the lack of 
evidence that chlamydia screening is effective in decreasing 
prevalence, it might be more effective to focus on women at 
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Figure 2 Forest plot of various sensitivity analyses of the risk for pelvic inflammatory disease (PID), ectopic pregnancy and tubal factor infertility 
(TFI) between chlamydia-positive and chlamydia-negative women in HRs and 95% CI. CSI, Chlamydia Screening Implementation.
key messages
 ► Estimating risks of Chlamydia trachomatis–related sequelae 
is difficult due to the asymptomatic nature of infection, other 
causes involved and time duration between infection and 
complications.
 ► In this long-term observational cohort study of women of 
reproductive age, chlamydia was measured using nucleic 
acid amplification test outcomes, serology and self-reported 
infections with 30% chlamydia positivity.
 ► Women who had chlamydia were at higher risk for pelvic 
inflammatory disease (twofold) and tubal factor infertility 
(fourfold), but not for ectopic pregnancy. Incidences rates, 
however, were small.
 ► Targeting women at highest risk for complications might 
be a more effective strategy to prevent Chlamydia-related 
complications than widespread Chlamydia screening.
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